Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
24.6 kDa. DTT-reduced protein migrates as 35 kDa due to glycosylation
HEK 293 Cells
Greater than 85% by SDS-PAGE
Measured by its binding ability in a functional ELISA. 1 µg/ml of rhFGF-BP was mixed with serially diluted rhFGF basic. Following incubation, the FGFBP-FGF basic complex was captured on a Gt x hFGFBP-coated plate. Bound FGF basic was measured using biotinylated Gt x hFGF basic. The concentration of rhFGF basic that produces 50% of the optimal binding was found to be approximately 10 - 50 ng/ml.
Less than 1.0 EU/µg protein (determined by LAL method).
Lyophilized from PBS, pH 7.4, mannitol or trehalose
Centrifuge the vial before opening. Reconstitute in sterile PBS, pH 7.4 to 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, store at -20°C.
FGFBP1 Protein, 17 kDa HBGF-binding protein Protein, FGF-BP Protein, HBP17 Protein, FGF-binding protein 1 Protein, FGFBP-1 Protein, FGF-BP1 Protein, FGFBP Protein
HBP17 / FGFBP1 is a secreted fibroblast growth factor carrier protein. The encoded protein plays a critical role in cell proliferation, differentiation and migration by binding to fibroblast growth factors and potentiating their biological effects on target cells. The encoded protein may also play a role in tumor growth as an angiogenic switch molecule, and expression of this gene has been associated with several types of cancer including pancreatic and colorectal adenocarcinoma.